← Azimuth Daily
Capturing data…
Capturing data…
SAT, 7 NOV · 88 ITEMS
"First vaccine trial against Bundibugyo virus begins in DR Congo" — The Lancet (current) · Science & Medicine
The first clinical trial of vaccines specifically targeting the , a species of ebolavirus, has begun in the Democratic Republic of the Congo. The trial, named Tumaini, is a Phase 2/3 study that will evaluate vaccine candidates during the ongoing Bundibugyo virus outbreak. The first participant was vaccinated in Bunia, DRC, on 23 October 2026, as announced by and WHO.
The claim is based on official announcements from CEPI and WHO, which are primary sources. The Lancet article (S0140-6736(26)02239-7) likely provides further details, and multiple news outlets confirm the start of the trial, making the claim well-supported.
Genuinely new; the trial began in October 2026, with announcements made on 23–24 October 2026.
We covered the emergence of a Bundibugyo virus variant in the 2026 outbreak in August 2026, and the outbreak situation report from early August 2026.